niclosamide

Niclosamide is a classic salicylanilide antiparasitic drug and a multi-target, low-toxicity, broad-spectrum small-molecule modulator with anthelmintic and antitumor activity. Niclosamide disrupts the parasite’s energy metabolism by uncoupling mitochondrial oxidative phosphorylation, leading to reduced ATP production and ultimately killing the parasite. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells.

Niclosamide olamine (Niclosamide Ethanolamine salt) is an Repellent, Insect Attractant and Chemosterilant.

Niclosamide Monohydrate is used for the treatment of most tapeworm infections by inhibiting DNA replication.

Niclosamide sodium (BAY2353), an orally active antihelminthic agent employed in parasitic infection research, serves as a potent STAT3 inhibitor, demonstrating an IC50 of 0.25 μM in HeLa cells. Additionally, this compound exhibits significant biological activities against cancer and effectively inhibits DNA replication in Vero E6 cells.

Niclosamide-13C6 is the 13C6-labeled form of Niclosamide. Niclosamide (T0711) (BAY2353) is an orally bioavailable chlorinated salicylanilide with anthelmintic and potential antineoplastic properties. It inhibits STAT3 with an IC50 of 0.25 μM in HeLa cells and suppresses DNA replication in cell-free assays.

Niclosamide (Standard) is the standard substance of Niclosamide, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Niclosamide (Niclocide)(BAY2353) is used to treat most tapeworm infections by inhibiting DNA replication.

Niclosamide olamine (Standard) is the standard substance of Niclosamide olamine, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Niclosamide olamine (Niclosamide Ethanolamine salt) is an Repellent, Insect Attractant and Chemosterilant.

TFM is a piscicide.1It is toxic to sea lamprey (P. marinus) with LC50values ranging from 1.97 to 2.11 and 2.05 to 2.21 mg/L for sac and swim-up fry, respectively, 1.6 to 2.45 mg/L for juveniles, and 1.6 to 1.63 mg/L for adults. It is also toxic to juvenile lake sturgeon (A. fulvescens) less than 100 mm in size but not to a variety of other fish species. TFM (50 μM) uncouples oxidative phosphorylation by 22 and 28% in isolated sea lamprey and rainbow trout (O. mykiss) liver, respectively.2Formulations containing TFM have been used as lampricides in the control of larval sea lamprey populations. 1.Boogaard, M.A., Bills, T.D., and Johnson, D.A.Acute toxicity of TFM and a TFM/niclosamide mixture to selected species of fish, including lake sturgeon (Acipenser fulvescens) and mudpuppies (Necturus maculosus), in laboratory and field exposuresJ. Great Lakes Res.29(Suppl 1)529-541(2003) 2.Birceanu, O., McClelland, G.B., Wang, Y.S., et al.The lampricide 3-trifluoromethyl-4-nitrophenol (TFM) uncouples mitochondrial oxidative phosphorylation in both sea lamprey (Petromyzon marinus) and TFM-tolerant rainbow trout (Oncorhynchus mykiss)Comp. Biochem. Physiol. C. Toxicol. Pharmacol.153(3)342-349(2011)

SARS-CoV-2-IN-14 is a potent and oral inhibitor of SARS-CoV-2 (IC50:0.39 μM), which is an analogue of niclosamide. SARS-CoV-2-IN-14 was more stable than niclosamide in the determination of human plasma and liver S9 enzyme. Oral administration of SARS-CoV-2-IN-14 can improve its bioavailability and half-life.

SARS-CoV-2-IN-15 (compound 11) is a niclosamide analogue exhibiting greater stability in human plasma and liver S9 enzyme assays compared to niclosamide. It enhances bioavailability and half-life upon oral administration and is a potent SARS-CoV-2 inhibitor with an IC50 of 0.49 μM [1].

SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide, displaying greater stability in human plasma and liver S9 enzymes assay. It improves bioavailability and half-life when administered orally and is a potent SARS-CoV-2 inhibitor with an IC50 of 0.057 μM [1].

JMX0312 is a salicylamide derivative used as a potent inhibitor of HAdV infection. JMX0312 showed significantly improved anti-HAdV activities with nanomolar to submicromolar IC50 values and high selectivity indexes (SI > 100), indicating better safety windows, compared to those of the lead compound niclosamide.

JMX0207 is a niclosamide-derived compound that demonstrates enhanced inhibitory efficacy against the NS3–NS2B protein-protein interaction essential for viral protease activity.JMX0207 effectively suppresses viral replication and protease function, showing superior antiviral activity in cell-based assays and significantly reducing Zika virus infection levels in three-dimensional mini-brain organoid models derived from pluripotent neural stem cells, thus highlighting its promise as an optimized antiviral lead compound.